Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Spartalizumab · PDR-001

Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PDCD1) · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer

What is Spartalizumab?

Spartalizumab is a humanized IgG4 monoclonal antibody that binds PD-1 on activated T cells and blocks its ligands PD-L1 and PD-L2, relieving PD-1-mediated inhibition of T-cell activation. It is being studied in non-small-cell lung carcinoma, melanoma, nasopharyngeal carcinoma, microsatellite stable colorectal cancer and triple negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PDR-001
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PDCD1), Programmed death-ligand 1 (CD274) (binding partner it blocks), Programmed death-ligand 2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Inhibitor of Programmed cell death protein 1 (PDCD1)
Pathways
PD-1 signaling, T-cell activation
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
QOG25L6Z8Z

Conditions studied

Carcinoma, Non-Small-Cell LungMelanomaMicrosatellite Stable Colorectal CancerNasopharyngeal CarcinomaTriple Negative Breast Cancer

Other drugs acting on PDCD1

More from Novartis Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Spartalizumab

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.